Stephen Begbie

6.3k total citations · 1 hit paper
23 papers, 1.1k citations indexed

About

Stephen Begbie is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Stephen Begbie has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Stephen Begbie's work include Prostate Cancer Treatment and Research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Renal cell carcinoma treatment (3 papers). Stephen Begbie is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Renal cell carcinoma treatment (3 papers). Stephen Begbie collaborates with scholars based in Australia, Canada and United States. Stephen Begbie's co-authors include Valentina Tzekova, Kurt Krejcy, Eckart Laack, Patrick Peterson, Joo Hang Kim, Maciej Krzakowski, Yi‐Long Wu, Thomas Brodowicz, Jayaprakash Madhavan and William J. John and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and CHEST Journal.

In The Last Decade

Stephen Begbie

22 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

2009 832 citations Tudor–Eliade Ciuleanu, Thomas Brodowicz et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Begbie Australia	7	789	702	146	117	113	23	1.1k
Clarissa Baldotto Brazil	12	465 0.6×	395 0.6×	163 1.1×	142 1.2×	12 0.1×	37	816
Omalkhair Abulkhair Saudi Arabia	12	138 0.2×	426 0.6×	74 0.5×	269 2.3×	62 0.5×	28	751
Yoshiteru Sumiyoshi Japan	14	462 0.6×	155 0.2×	84 0.6×	64 0.5×	54 0.5×	52	773
Il Yong Chung South Korea	17	124 0.2×	448 0.6×	176 1.2×	420 3.6×	55 0.5×	110	1.0k
Friedrich Overkamp Germany	13	204 0.3×	356 0.5×	149 1.0×	206 1.8×	27 0.2×	64	592
Wolfgang Lilleby Norway	20	750 1.0×	451 0.6×	246 1.7×	165 1.4×	7 0.1×	77	1.2k
Omar El Mesbahi Morocco	13	129 0.2×	204 0.3×	50 0.3×	92 0.8×	33 0.3×	58	494
Antonio Di Meglio France	14	209 0.3×	382 0.5×	59 0.4×	86 0.7×	18 0.2×	67	571
Diane Severin Canada	16	225 0.3×	284 0.4×	100 0.7×	91 0.8×	12 0.1×	51	696
Nuttapong Ngamphaiboon Thailand	17	223 0.3×	515 0.7×	180 1.2×	124 1.1×	21 0.2×	73	896

Countries citing papers authored by Stephen Begbie

Since Specialization

Citations

This map shows the geographic impact of Stephen Begbie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Begbie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Begbie more than expected).

Fields of papers citing papers by Stephen Begbie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Begbie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Begbie. The network helps show where Stephen Begbie may publish in the future.

Co-authorship network of co-authors of Stephen Begbie

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Begbie. A scholar is included among the top collaborators of Stephen Begbie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Begbie. Stephen Begbie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mehra, Niven, Emmanuel S. Antonarakis, Se Hoon Park, et al.. (2025). Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer. European Urology Oncology. 8(4). 1030–1040. 1 indexed citations

Crumbaker, Megan, Mitchell G. Lawrence, Leonard D. Goldstein, et al.. (2025). A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).. Journal of Clinical Oncology. 43(5_suppl). 218–218.

Mehra, Niven, Emmanuel S. Antonarakis, Se Hoon Park, et al.. (2023). Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 131–131. 3 indexed citations

Kichenadasse, Ganessan, Carole A. Harris, Howard Gurney, et al.. (2022). Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4537–4537. 4 indexed citations

Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2021). UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.. Journal of Clinical Oncology. 39(6_suppl). 325–325. 2 indexed citations

Begbie, Stephen, Suzanne Kosmider, Sumitra Ananda, et al.. (2020). Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. Clinical Colorectal Cancer. 20(1). e21–e34. 7 indexed citations

Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2020). UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).. Journal of Clinical Oncology. 38(6_suppl). TPS768–TPS768. 1 indexed citations

Tognela, Annette, David Espinoza, Andrew R. Davidson, et al.. (2016). Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTG NITRO trial of 1st line chemotherapy for advanced non–small-cell lung cancer.. Journal of Clinical Oncology. 34(15_suppl). 9074–9074. 2 indexed citations

Courneya, Kerry S., Janette L. Vardy, Christopher J. O’Callaghan, et al.. (2016). Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.. Journal of Clinical Oncology. 34(15_suppl). 3621–3621. 1 indexed citations

10.

Booth, Christopher M., Janette L. Vardy, Christopher J. O’Callaghan, et al.. (2015). A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).. Journal of Clinical Oncology. 33(15_suppl). TPS3620–TPS3620. 1 indexed citations

11.

Chua, Yu Jo, Christos S. Karapetis, Val Gebski, et al.. (2014). Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.. Journal of Clinical Oncology. 32(3_suppl). 228–228. 3 indexed citations

12.

Woo, Henry H., Stephen Begbie, Paul N. Mainwaring, et al.. (2014). Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice. Asia-Pacific Journal of Clinical Oncology. 10(3). 228–236. 2 indexed citations

13.

Booth, Christopher M., Janette L. Vardy, Sharlene Gill, et al.. (2014). A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).. Journal of Clinical Oncology. 32(15_suppl). TPS3663–TPS3663. 1 indexed citations

14.

Underhill, Craig, David Goldstein, Stephen Begbie, et al.. (2009). Mapping oncology services in regional and rural Australia. Australian Journal of Rural Health. 17(6). 321–329. 82 indexed citations

15.

Khasraw, Mustafa, Nick Pavlakis, Craig Underhill, et al.. (2009). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology. 21(6). 1302–1307. 44 indexed citations

16.

Ciuleanu, Tudor–Eliade, Thomas Brodowicz, Christoph Zielinski, et al.. (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet. 374(9699). 1432–1440. 832 indexed citations breakdown →

17.

Begbie, Stephen & Craig Underhill. (2007). Cancer services to be proud of in rural Australia: lessons learnt from the Clinical Oncological Society of Australia cancer service audit. Cancer Forum. 31(2). 90. 11 indexed citations

18.

Marx, Gavin, et al.. (2005). ProTat: A phase II trial of docetaxel (D), prednisolone (P) and thalidomide (T) in patients with androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 23(16_suppl). 4672–4672. 1 indexed citations

19.

Begbie, Stephen, et al.. (1997). Mediastinal Epithelioid Hemangioendothelioma in a Patient with Type IV Ehlers-Danlos Syndrome: A Case Report and Review of the Literature. American Journal of Clinical Oncology. 20(4). 412–415. 9 indexed citations

20.

Begbie, Stephen & Keith R. Burgess. (1993). Maloprlm-Induced Pulmonary Eosinophilia. CHEST Journal. 103(1). 305–306. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact